CFAI
C.F.A.I.
Government Data Intelligence Services

LEO PHARMA INC

Company NJ
Found in 3 federal databases · 5 total records
fda 3 records
FDA Drug Recall: Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose 2026-03-04
Class II — Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
View Source
FDA Drug Recall: Calcipotriene Cream 0.0005%, packaged in a) 60g tube, (NDC 66993-877-61), b) 120 2017-03-15
Class II — Incorrect/Undeclared excipients: inadvertent omission of a drug excipient from the the Authorized Generic label and also a warning regarding contact dermatitis from the brand product labeli...
View Source
FDA Drug Recall: Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.0 2017-02-22
Class III — Labeling: Incorrect or missing package insert: the affected product was packaged with an out-of-date package insert (PI) dated February 2014.
View Source
fda_adverse 1 records
FDA AE Manufacturer: LEO Pharma Inc.
Drug adverse event reporter — Product: ADBRY
View Source
ny_corps 1 records
NY Corp: LEO PHARMA INC. 2016-08-16
FOREIGN BUSINESS CORPORATION | County: New York | Jurisdiction: Delaware
View Source
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.